Revenue beat consensus by 41% but the beat is largely from non-recurring R&D milestone payments; watch for the zilganersen PDUFA on Sep 22, 2026 and the pelacarsen Lp(a) HORIZON data later this year as the next major catalysts. The CARDIO-TTRansform miss removes a potential upside driver for eplontersen royalties.
Drugs in focus
IONS drug pipeline →diranersen
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2 (topline readout complete; confirmatory Phase 3 announced but not yet started)
- Time to market
- Unknown and several years away — a confirmatory Phase 3 program has not even started; the completed Phase 2 CELIA trial's estimated overall completion is January 2029, so a registration and launch would come later than that if Phase 3 succeeds.
- Next catalyst
- None dated
What to watchWatch for Biogen's announcement of the Phase 3 program design, start date, and endpoints, that will be the next share-moving event, but it is likely months away and not a binary. Near-term BIIB stock moves are driven mostly by the commercial franchises (LEQEMBI, SPINRAZA) and other pipeline news, not diranersen, so treat this as years-out call-option value rather than a trade catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 29 $54.04entry
- T+1 · 4mo ago −1.41%α −3.08% · $53.28
- T+5 · 3mo ago +0.28%α −5.25% · $54.19
- T+20 · 3mo ago +17.25%α +12.23% · $63.36
- T+60 · 26d ago −18.75%α −23.47% · $43.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ionis reported Q2 2026 total revenue of $268M, up 56% YoY excluding a one-time 2025 sapablursen payment, but GAAP net loss widened to $115M from a $124M profit in Q2 2025 which included a $280M upfront. Commercial revenue grew 15% YoY driven by DAWNZERA ($26M, +63% QoQ) and early TRYNGOLZA sHTG launch momentum. The company maintained full-year 2026 guidance and reiterated its 2028 cash-flow breakeven target.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $268M vs $452M in Q2 2025 (Q2 2025 included $280M sapablursen upfront); ex that item, revenue +56% YoY
- Non-GAAP net loss $70M vs non-GAAP net income $154M in Q2 2025
- TRYNGOLZA net product sales $5M in Q2, $32M H1; on track for full-year $100-110M guidance
- DAWNZERA net product sales $26M in Q2, +63% QoQ; on track for full-year $110-120M guidance
- Cash and short-term investments $2.1B at June 30, 2026, down from $2.7B at Dec 31, 2025 due to convertible note repayment
- Phase 3 CARDIO-TTRansform study of eplontersen in ATTR-CM missed primary composite endpoint
- Full-year 2026 guidance maintained: total revenue $875-900M, non-GAAP operating loss $425-475M
Financial Impact
Q2 revenue $268M (consensus $190.1M); GAAP EPS -$0.69 (consensus -$0.88); beat on both lines
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Commercial revenue | $119.0M | +15.5% |
| R&D revenue | $149.0M | Not reported |
Risk Factors
- CARDIO-TTRansform miss reduces WAINUA ATTR-CM opportunity
- TRYNGOLZA sHTG launch still early; full-year guidance implies significant H2 ramp
- Operating cash burn continues; $2.1B cash runway supports operations but convertible debt maturities remain
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-029960 |
| Document: ef20078953_8k.htm | 0001140361-26-029960 |
| Document: 0001140361-26-029960-index-headers.html | 0001140361-26-029960 |
| Document: 0001140361-26-029960-index.html | 0001140361-26-029960 |
| Document: 0001140361-26-029960.txt | 0001140361-26-029960 |
| 8-K Data (Synthetic) | 0001140361-26-029960 |
Track record
26 reports on IONS
7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +32.25% at T+60 after the Jul 9, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $31.00 to $28.01 Now $28.01 +9.65% ▲ +9.65% +7.95% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $44.90 to $40.15 Now $28.01 −37.62% ▼ −10.58% −9.87% vs SPY
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $42.93 to $43.52 Now $28.01 −34.75% ▲ +1.37% +1.93% vs SPY
- Oct 21, 202626d ago 8-K Bullish 7/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
- Oct 21, 202626d ago Institutional Cluster Mixed 3/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
- Sep 23, 20267w ago 8-K Bullish 7/10 Entry $43.93 to $44.65 Now $28.01 −36.24% ▲ +1.64% +2.31% vs SPY
- Sep 4, 202610w ago 8-K Bearish 7/10 Entry $56.71 to $47.25 Now $28.01 +50.61% ▲ +16.68% +15.56% vs SPY
- Sep 4, 202610w ago 8-K Bullish 7/10 Entry $58.09 to $51.44 Now $28.01 −51.78% ▼ −11.45% −10.24% vs SPY
- Jul 31, 202615w ago Insider Buy Neutral 4/10 Entry $54.49 to $56.94 Now $28.01 −48.60% ▲ +4.50% +2.47% vs SPY
- Jul 29, 202615w ago 8-K Neutral 5/10 Viewing Entry $54.04 to $54.19 Now $28.01 −48.17% ▲ +0.28% −5.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers